Richmond, Va (August 2, 2022) – Kaléo, a privately held U.S. pharmaceutical company, today announced that
it has entered into a ten-year License, Supply, and Commercialization agreement with Valeo Pharma, a
Canadian pharmaceutical company, for the Canadian rights to ALLERJECT® (epinephrine injection, USP) for the
treatment of severe allergic reactions.
“Patients with life threatening allergies across Canada deserve access to this innovative and potentially
lifesaving product,” said Kaléo President and CEO Ronald Gunn. “Valeo Pharma’s sales force, relationships with
the healthcare community, and commitment to patients make them the ideal partner for ALLERJECT.”
For more information please visit valeopharma.com/news.